[Short-term effect of an estroprogestin containing ethinylestradiol 20 mcg + drospirenone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism].

Abstract

AIM:

evaluate the efficacy of an estroprogestin EP containing 20 mcg ethinilestradiol (EE) and 3 mg drospirenone (DRSP) in the treatment of hyperandrogenism.

METHODS:

In this study, twenty hyperandrogenic patients were treated with an EP containing EE 20 mcg and DRSP 3 mg in 24+4 regimen for three months. Skin evaluation was performed both quantitatively and qualitatively.

RESULTS AND CONCLUSION:

This EP combination showed, after a short-term treatment (three months) to decrease significantly seborrhea, acne, and circulating androgens (testosterone, deidroepiandrosterone sulphate, and androstenedione), while increased sex hormone binding globulin levels. Moreover, this EE 20 mcg/DRSP 3mg EP combination changed some parameters of skin quality, increasing corneometry (a parameter related to skin hydration), and reduced trans epidermal water loss (TEWL, a parameter related to skin evaporation), and erythema (a parameter related to skin inflammation). These results could be taken into account in individualizing the treatment of hyperandrogenic patients.

• Authors: S Lello, V Pacifico, G Primavera, F Guardianelli, R Sorge, A M Paoletti, G B Melis, D Raskovic, L Colonna
• Journal: Minerva ginecologica (Minerva Ginecol) Vol. 62 Issue 6 Pg. 509-13 (Dec 2010) ISSN: 0026-4784 [Print] Italy
• Vernacular Title: Effecto a breve termine di un estroprogestinico contenente etinilestradiolo 20 mcg+drospirenone 3mg in schema 24 + 4 a livello ormonale e cutaneo nell'iperandrogenismo ovarico.
• PMID: 21079572 (Publication Type: English Abstract, Journal Article)

Chemical References

• Androstenes
• Drug Combinations
• Estrogens
• Mineralocorticoid Receptor Antagonists
• Norpregnenes
• estroprogestin
• Ethinyl Estradiol
• drospirenone

Topics

• Administration, Oral
• Adolescent
• Adult
• Androstenes (administration & dosage)
• Drug Combinations
• Estrogens (administration & dosage)
• Ethinyl Estradiol (administration & dosage)
• Female
• Humans
• Hyperandrogenism (diagnosis, drug therapy)
• Mineralocorticoid Receptor Antagonists (administration & dosage)
• Norpregnenes
• Severity of Illness Index
• Time Factors
• Treatment Outcome